MAPT and dementia: Neuroimaging and biomarker assessments (e.g., Tau protein and Amyloid deposition) offer more objective and sensitive measures that can enhance diagnostic accuracy by providing insights into underlying neuropathological changes associated with MCI and its progression to dementia.